|
1
|
Nayak L, Lee EQ and Wen PY: Epidemiology
of brain metastases. Curr Oncol Rep. 14:48–54. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin X and DeAngelis LM: Treatment of brain
metastases. J Clin Oncol. 33:3475–3484. 2015. View Article : Google Scholar
|
|
3
|
Sacks P and Rahman M: Epidemiology of
brain metastases. Neurosurg Clin N Am. 31:481–488. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bhambhvani HP, Granucci M, Rodrigues A,
Kakusa BW and Hayden Gephart M: The primary sites leading to brain
metastases: Shifting trends at a tertiary care center. J Clin
Neurosci. 80:121–124. 2020. View Article : Google Scholar
|
|
5
|
Ostrom QT, Wright CH and Barnholtz-Sloan
JS: Brain metastases: Epidemiology. Handb Clin Neurol. 149:27–42.
2018. View Article : Google Scholar
|
|
6
|
Tabouret E, Chinot O, Metellus P, Tallet
A, Viens P and Gonçalves A: Recent trends in epidemiology of brain
metastases: An overview. Anticancer Res. 32:4655–4662.
2012.PubMed/NCBI
|
|
7
|
Hsu F, De Caluwe A, Anderson D, Nichol A,
Toriumi T and Ho C: Patterns of spread and prognostic implications
of lung cancer metastasis in an era of driver mutations. Curr
Oncol. 24:228–233. 2017. View Article : Google Scholar
|
|
8
|
Pestalozzi BC, Zahrieh D, Price KN,
Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E,
Pagani O, et al: Identifying breast cancer patients at risk for
Central Nervous System (CNS) metastases in trials of the
International Breast Cancer Study Group (IBCSG). Ann Oncol.
17:935–944. 2006. View Article : Google Scholar
|
|
9
|
Arvanitis CD, Ferraro GB and Jain RK: The
blood-brain barrier and blood-tumour barrier in brain tumours and
metastases. Nat Rev Cancer. 20:26–41. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McTyre E, Scott J and Chinnaiyan P: Whole
brain radiotherapy for brain metastasis. Surg Neurol Int. 4 (Suppl
4):S236–S244. 2013. View Article : Google Scholar
|
|
11
|
Mehta SR, Suhag V, Semwal M and Sharma N:
Radiotherapy: Basic concepts and recent advances. Med J Armed
Forces India. 66:158–162. 2010. View Article : Google Scholar
|
|
12
|
Gelband H, Jha P, Sankaranarayanan R and
Horton S: Cancer: Disease Control Priorities. Third Edition.
(Volume 3). The International Bank for Reconstruction and
Development/The World Bank; Washington, D.C.: 2015
|
|
13
|
Xing L, Thorndyke B, Schreibmann E, Yang
Y, Li TF, Kim GY, Luxton G and Koong A: Overview of image-guided
radiation therapy. Med Dosim. 31:91–112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Otto K: Volumetric modulated arc therapy:
IMRT in a single gantry arc. Med Phys. 35:310–317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sapkaroski D, Osborne C and Knight KA: A
review of stereotactic body radiotherapy-is volumetric modulated
arc therapy the answer? J Med Radiat Sci. 62:142–151. 2015.
View Article : Google Scholar
|
|
16
|
DeAngelis LM, Delattre JY and Posner JB:
Radiation-induced dementia in patients cured of brain metastases.
Neurology. 39:789–796. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ali FS, Arevalo O, Zorofchian S, Patrizz
A, Riascos R, Tandon N, Blanco A, Ballester LY and Esquenazi Y:
Cerebral radiation necrosis: Incidence, pathogenesis, diagnostic
challenges, and future opportunities. Curr Oncol Rep. 21:662019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JM, Miller JA, Kotecha R, Xiao R,
Juloori A, Ward MC, Ahluwalia MS, Mohammadi AM, Peereboom DM,
Murphy ES, et al: The risk of radiation necrosis following
stereotactic radiosurgery with concurrent systemic therapies. J
Neurooncol. 133:357–368. 2017. View Article : Google Scholar
|
|
19
|
Donovan EK, Parpia S and Greenspoon JN:
Incidence of radionecrosis in single-fraction radiosurgery compared
with fractionated radiotherapy in the treatment of brain
metastasis. Curr Oncol. 26:e328–e333. 2019. View Article : Google Scholar
|
|
20
|
Vellayappan BA, McGranahan T, Graber J,
Taylor L, Venur V, Ellenbogen R, Sloan AE, Redmond KJ, Foote M,
Chao ST, et al: Radiation necrosis from stereotactic
radiosurgery-how do we mitigate? Curr Treat Options Oncol.
22:572021. View Article : Google Scholar
|
|
21
|
Minniti G, Clarke E, Lanzetta G, Osti MF,
Trasimeni G, Bozzao A, Romano A and Enrici RM: Stereotactic
radiosurgery for brain metastases: Analysis of outcome and risk of
brain radionecrosis. Radiat Oncol. 6:482011. View Article : Google Scholar
|
|
22
|
Kohutek ZA, Yamada Y, Chan TA, Brennan CW,
Tabar V, Gutin PH, Yang TJ, Rosenblum MK, Ballangrud Å, Young RJ,
et al: Long-term risk of radionecrosis and imaging changes after
stereotactic radiosurgery for brain metastases. J Neurooncol.
125:149–156. 2015. View Article : Google Scholar
|
|
23
|
Shaw E, Scott C, Souhami L, Dinapoli R,
Kline R, Loeffler J and Farnan N: Single dose radiosurgical
treatment of recurrent previously irradiated primary brain tumors
and brain metastases: Final report of RTOG protocol 90-05. Int J
Radiat Oncol Biol Phys. 47:291–298. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Loo M, Clavier JB, Attal Khalifa J, Moyal
E and Khalifa J: Dose-Response effect and dose-toxicity in
stereotactic radiotherapy for brain metastases: A review. Cancers
(Basel). 13:60862021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Putz F, Weissmann T, Oft D, Schmidt MA,
Roesch J, Siavooshhaghighi H, Filimonova I, Schmitter C, Mengling
V, Bert C, et al: FSRT vs. SRS in brain metastases-differences in
local control and radiation Necrosis-A volumetric study. Front
Oncol. 10:5591932020. View Article : Google Scholar
|
|
26
|
Brown PD, Jaeckle K, Ballman KV, Farace E,
Cerhan JH, Anderson SK, Carrero XW, Barker FG II, Deming R, Burri
SH, et al: Effect of radiosurgery alone vs. radiosurgery with whole
brain radiation therapy on cognitive function in patients with 1 to
3 brain metastases: A randomized clinical trial. JAMA. 316:401–409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamamoto M, Serizawa T, Shuto T, Akabane
A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S, et
al: Stereotactic radiosurgery for patients with multiple brain
metastases (JLGK0901): A multi-institutional prospective
observational study. Lancet Oncol. 15:387–395. 2014. View Article : Google Scholar
|
|
28
|
Patchell RA, Tibbs PA, Regine WF, Dempsey
RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA and Young B:
Postoperative radiotherapy in the treatment of single metastases to
the brain: A randomized trial. JAMA. 280:1485–1489. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Patchell RA, Tibbs PA, Walsh JW, Dempsey
RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young
B: A randomized trial of surgery in the treatment of single
metastases to the brain. N Engl J Med. 322:494–500. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kayama T, Sato S, Sakurada K, Mizusawa J,
Nishikawa R, Narita Y, Sumi M, Miyakita Y, Kumabe T, Sonoda Y, et
al: Effects of surgery with salvage stereotactic radiosurgery
versus surgery with whole-brain radiation therapy in patients with
one to four brain metastases (JCOG0504): A phase III,
noninferiority, randomized controlled trial. J Clin Oncol.
JCO20187861862018.
|
|
31
|
Brown PD, Ballman KV, Cerhan JH, Anderson
SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI,
Ashman JB, et al: Postoperative stereotactic radiosurgery compared
with whole brain radiotherapy for resected metastatic brain disease
(NCCTG N107C/CEC·3): A multicentre, randomised, controlled, phase 3
trial. Lancet Oncol. 18:1049–1060. 2017. View Article : Google Scholar
|
|
32
|
Kępka L, Tyc-Szczepaniak D, Bujko K,
Olszyna-Serementa M, Michalski W, Sprawka A, Trąbska-Kluch B,
Komosińska K, Wasilewska-Teśluk E and Czeremszyńska B: Stereotactic
radiotherapy of the tumor bed compared to whole brain radiotherapy
after surgery of single brain metastasis: Results from a randomized
trial. Radiother Oncol. 121:217–224. 2016. View Article : Google Scholar
|
|
33
|
Randall Patrinely J Jr, Funck-Brentano E,
Nguyen K, Rapisuwon S, Salem JE, Gibney GT, Carlino M and Johnson
DB: A multicenter analysis of immune checkpoint inhibitors as
adjuvant therapy following treatment of isolated brain metastasis.
Oncologist. 26:e505–e507. 2021. View Article : Google Scholar
|
|
34
|
Vogelbaum MA, Brown PD, Messersmith H,
Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN,
Gondi V, et al: Treatment for brain metastases: ASCO-SNO-ASTRO
guideline. J Clin Oncol. 40:492–516. 2022. View Article : Google Scholar
|
|
35
|
Rusthoven CG, Yamamoto M, Bernhardt D,
Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T,
et al: Evaluation of first-line radiosurgery vs. whole-brain
radiotherapy for small cell lung cancer brain metastases: The
FIRE-SCLC Cohort Study. JAMA Oncol. 6:1028–1037. 2020. View Article : Google Scholar
|
|
36
|
Aupérin A, Arriagada R, Pignon JP, Le
Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka
H, Wagner H and Aisner J: Prophylactic cranial irradiation for
patients with small-cell lung cancer in complete remission.
Prophylactic Cranial Irradiation Overview Collaborative Group. N
Engl J Med. 341:476–484. 1999. View Article : Google Scholar
|
|
37
|
Arriagada R, Le Chevalier T, Borie F,
Rivière A, Chomy P, Monnet I, Tardivon A, Viader F, Tarayre M and
Benhamou S: Prophylactic cranial irradiation for patients with
small-cell lung cancer in complete remission. J Natl Cancer Inst.
87:183–190. 1995. View Article : Google Scholar
|
|
38
|
Yin X, Yan D, Qiu M, Huang L and Yan SX:
Prophylactic cranial irradiation in small cell lung cancer: A
systematic review and meta-analysis. BMC Cancer. 19:952019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pezzi TA, Fang P, Gjyshi O, Feng L, Liu S,
Komaki R and Lin SH: Rates of overall survival and intracranial
control in the magnetic resonance imaging Era for patients with
limited-stage small cell lung cancer with and without prophylactic
cranial irradiation. JAMA Netw Open. 3:e2019292020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan
T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in
targeted cancer therapy: Advances, challenges, and future
perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ramalingam SS, Vansteenkiste J, Planchard
D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y,
Chewaskulyong B, et al: Overall Survival with Osimertinib in
Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 382:41–50.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ando K, Manabe R, Kishino Y, Kusumoto S,
Yamaoka T, Tanaka A, Ohmori T and Sagara H: Comparative efficacy
and safety of lorlatinib and alectinib for ALK-Rearrangement
positive advanced non-small cell lung cancer in asian and non-asian
patients: A systematic review and network meta-analysis. Cancers
(Basel). 13:37042021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shaw AT, Bauer TM, de Marinis F, Felip E,
Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, et al:
First-Line lorlatinib or crizotinib in advanced ALK-positive lung
cancer. N Engl J Med. 383:2018–2029. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Narita Y, Nagane M, Mishima K, Terui Y,
Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N,
et al: Phase I/II study of tirabrutinib, a second-generation
Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary
central nervous system lymphoma. Neuro Oncol. 23:122–133. 2021.
View Article : Google Scholar
|
|
45
|
Murthy RK, Loi S, Okines A, Paplomata E,
Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, et
al: Tucatinib, trastuzumab, and capecitabine for HER2-Positive
metastatic breast cancer. N Engl J Med. 382:597–609. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang PW and Chang JW: Immune checkpoint
inhibitors win the 2018 Nobel Prize. Biomed J. 42:299–306. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Corroyer-Dulmont A, Jaudet C, Frelin AM,
Fantin J, Weyts K, Vallis KA, Falzone N, Sibson NR, Chérel M,
Kraeber-Bodéré F, et al: Radioimmunotherapy for brain metastases:
The potential for inflammation as a target of choice. Front Oncol.
11:7145142021. View Article : Google Scholar
|
|
48
|
Goldberg SB, Gettinger SN, Mahajan A,
Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A,
Jilaveanu L, et al: Pembrolizumab for patients with melanoma or
non-small-cell lung cancer and untreated brain metastases: Early
analysis of a non-randomised, open-label, phase 2 trial. Lancet
Oncol. 17:976–983. 2016. View Article : Google Scholar
|
|
49
|
Tawbi HA, Forsyth PA, Hodi FS, Algazi AP,
Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, et al:
Long-term outcomes of patients with active melanoma brain
metastases treated with combination nivolumab plus ipilimumab
(CheckMate 204): Final results of an open-label, multicentre, phase
2 study. Lancet Oncol. 22:1692–1704. 2021. View Article : Google Scholar
|
|
50
|
Gaspar L, Scott C, Rotman M, Asbell S,
Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive
partitioning analysis (RPA) of prognostic factors in three
Radiation Therapy Oncology Group (RTOG) brain metastases trials.
Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar
|
|
52
|
Sperduto PW, Berkey B, Gaspar LE, Mehta M
and Curran W: A new prognostic index and comparison to three other
indices for patients with brain metastases: An analysis of 1,960
patients in the RTOG database. Int J Radiat Oncol Biol Phys.
70:510–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sperduto PW, Kased N, Roberge D, Xu Z,
Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, et al: Summary
report on the graded prognostic assessment: An accurate and facile
diagnosis-specific tool to estimate survival for patients with
brain metastases. J Clin Oncol. 30:419–425. 2012. View Article : Google Scholar
|
|
54
|
Sperduto PW, Yang TJ, Beal K, Pan H, Brown
PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, et al:
Estimating survival in patients with lung cancer and brain
metastases: An update of the graded prognostic assessment for lung
cancer using molecular markers (Lung-molGPA). JAMA Oncol.
3:827–831. 2017. View Article : Google Scholar
|
|
55
|
Sperduto PW, Mesko S, Li J, Cagney D,
Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, et al:
Beyond an updated graded prognostic assessment (Breast GPA): A
prognostic index and trends in treatment and survival in breast
cancer brain metastases from 1985 to today. Int J Radiat Oncol Biol
Phys. 107:334–343. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mulvenna P, Nankivell M, Barton R,
Faivre-Finn C, Wilson P, McColl E, Moore B, Brisbane I, Ardron D,
Holt T, et al: Dexamethasone and supportive care with or without
whole brain radiotherapy in treating patients with non-small cell
lung cancer with brain metastases unsuitable for resection or
stereotactic radiotherapy (QUARTZ): Results from a phase 3,
non-inferiority, randomised trial. Lancet. 388:2004–2014. 2016.
View Article : Google Scholar
|
|
57
|
Lin B, Gao F, Yang Y, Wu D, Zhang Y, Feng
G, Dai T and Du X: FLASH radiotherapy: History and future. Front
Oncol. 11:6444002021. View Article : Google Scholar
|
|
58
|
Montay-Gruel P, Acharya MM, Petersson K,
Alikhani L, Yakkala C, Allen BD, Ollivier J, Petit B, Jorge PG,
Syage AR, et al: Long-term neurocognitive benefits of FLASH
radiotherapy driven by reduced reactive oxygen species. Proc Natl
Acad Sci USA. 116:10943–10951. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shepard MJ, Xu Z, Donahue J, Eluvathingal
Muttikkal TJ, Cordeiro D, Hansen L, Mohammed N, Gentzler RD, Larner
J, Fadul CE and Sheehan JP: Stereotactic radiosurgery with and
without checkpoint inhibition for patients with metastatic
non-small cell lung cancer to the brain: A matched cohort study. J
Neurosurg. 133:685–692. 2019. View Article : Google Scholar
|
